Diagnosis of aHUS C3 involves a combination of clinical performance, imaging, laboratory testing and pathological activation. The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. Treatment and management of aHUS C3 involves the development of personalized treatment plans, typically including drug therapy, rehabilitation interventions, regular follow-up visits, and more.
In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, according to timely adjustments to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of aHUS C3.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.